DDInter1036 DDInter1435
Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4; the platelet derived growth factor receptor alpha (PDGFRα), KIT, and RET. These receptor tyrosine kinases (RTKs) located in the cell membrane play a central role in the activation of signal transduction pathways involved in the normal regulation of cellular processes, such as cell proliferation, migration, apoptosis and differentiation, and in pathogenic angiogenesis, lymphogenesis, tumour
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Lenvatinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Lenvatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Venlafaxine
Lenvatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tipiracil
Lenvatinib {u} may lead to a major life threatening interaction when taken with {v} Vandetanib
Lenvatinib {u} may lead to a major life threatening interaction when taken with {v} Ivosidenib
Lenvatinib may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Lenvatinib may cause a moderate interaction that could exacerbate diseases when taken with Venlafaxine
Lenvatinib may cause a moderate interaction that could exacerbate diseases when taken with Tipiracil
Lenvatinib may lead to a major life threatening interaction when taken with Vandetanib
Lenvatinib may lead to a major life threatening interaction when taken with Ivosidenib